What is the Chronic Graft-versus-host Disease Consortium?

The Chronic GVHD Consortium is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different immune mediated disorders after allogeneic hematopoietic cell transplantation and improving the care of patients affected by these disorders. Funded by the National Institutes of Health (NIH), the Chronic GVHD Consortium is part of the Rare Diseases Clinical Research Network. The operations of the Chronic GVHD Consortium are directed from Fred Hutchinson Cancer Research Center and the nine Primary Study Sites include Fred Hutchinson Cancer Research Center, Stanford University, University of Minnesota, Dana-Farber Cancer Institute, Vanderbilt, Medical College of Wisconsin, Moffitt Cancer Center, Washington University, and National Institutes of Health.

Mission

The Chronic Graft-versus-host Disease Consortium seeks to decrease illness, limit disability and prevent death for patients who develop immune-mediated complications after allogeneic hematopoietic cell transplantation.

Goals

Goals of the Chronic Graft-versus-host Disease Consortium are:

  1. To characterize the incidence, clinical manifestations and outcomes for patients who develop chronic graft-versus-host disease (GVHD), cutaneous sclerosis, bronchiolitis obliterans or late acute GVHD after allogeneic hematopoietic cell transplantation;
  2. To identify biomarkers that can assess risk, impending onset, diagnosis or prognosis of chronic GVHD, cutaneous sclerosis, bronchiolitis obliterans or late acute GVHD after allogeneic hematopoietic cell transplantation;
  3. To evaluate the efficacy of treatments for chronic GVHD, cutaneous sclerosis, bronchiolitis obliterans or late acute GVHD after allogeneic hematopoietic cell transplantation